Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bone Marrow
Filgrastim
/ pharmacology
Fluorouracil
Granulocyte Colony-Stimulating Factor
/ pharmacology
Granulocytes
Humans
Mice
Neutropenia
/ chemically induced
Polyethylene Glycols
Recombinant Proteins
/ adverse effects
Retrospective Studies
5-fluorouracil
Bone marrow
Mice
Neutropenia
Pegfilgrastim
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
06 Jun 2022
06 Jun 2022
Historique:
received:
11
01
2022
accepted:
01
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Granulocyte-colony stimulating factor (G-CSF) stimulates bone marrow progenitor cell proliferation and enhances neutrophil production. Exogenous G-CSF administration is indicated for chemotherapy-induced neutropenia management. However, there is a paucity of basic research examining the effects of the concomitant use of G-CSF and chemotherapy on myeloid cells in vivo. Whether concomitant G-CSF and chemotherapy adversely affect myeloid cell proliferation have not been determined. Herein, we examined the effects of the concomitant use of pegfilgrastim and 5-fluorouracil on myeloid cells and peripheral blood cells in mouse models. Balb/c mice were treated intraperitoneally with 5-fluorouracil (20 μg/g b.w.) or a vehicle as a control for 5 days, and pegfilgrastim was administered subcutaneously at 1 μg/g b.w. on day 3. As a result, we demonstrated that the concomitant use of pegfilgrastim suppressed the 5-fluorouracil-induced decrease of granulocytic cells in both bone marrow and peripheral blood in mice. To assess the clinical efficacy of early administration of pegfilgrastim during docetaxel, cisplatin, and 5-fluorouracil therapy in patients with esophageal cancer, we retrospectively identified 42 consecutive patients treated with this regimen. The incidence of both febrile neutropenia and grade 4 neutropenia was significantly lower in patients who received pegfilgrastim than in those who did not receive it (P = 0.002 and P = 0.002, respectively). These results suggest that the concomitant use of pegfilgrastim and chemotherapy, consisting of continuous infusions of 5-fluorouracil, improved chemotherapy-induced neutropenia without detrimental effects on proliferating myeloid granulocytic cells.
Identifiants
pubmed: 35666320
doi: 10.1007/s12032-022-01725-9
pii: 10.1007/s12032-022-01725-9
doi:
Substances chimiques
Recombinant Proteins
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Polyethylene Glycols
3WJQ0SDW1A
Filgrastim
PVI5M0M1GW
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K07787
Organisme : Japan Society for the Promotion of Science
ID : 17K09314.
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32. https://doi.org/10.1016/j.ejca.2010.10.013 .
doi: 10.1016/j.ejca.2010.10.013
pubmed: 21095116
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, et al. Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(12):1520–41. https://doi.org/10.6004/jnccn.2017.0175 .
doi: 10.6004/jnccn.2017.0175
pubmed: 29223990
Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer. Support Care Cancer. 2015;23(2):525–45. https://doi.org/10.1007/s00520-014-2457-z .
doi: 10.1007/s00520-014-2457-z
pubmed: 25284721
Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival. Ann Oncol. 2013;24(10):2475–84. https://doi.org/10.1093/annonc/mdt226 .
doi: 10.1093/annonc/mdt226
pubmed: 23788754
pmcid: 3841419
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, et al. Recommendations for the use of WBC growth factors. ASCO clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–212. https://doi.org/10.1200/JCO.2015.62.3488 .
doi: 10.1200/JCO.2015.62.3488
pubmed: 26169616
Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst. 1992;84(15):1201–3. https://doi.org/10.1093/jnci/84.15.1201 .
doi: 10.1093/jnci/84.15.1201
pubmed: 1378905
Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol. 1996;14:1224–35. https://doi.org/10.1200/JCO.1996.14.4.1224 .
doi: 10.1200/JCO.1996.14.4.1224
pubmed: 8648378
Yasuda T, Ishikawa T, Ohta T, Yoshida J, Doi T, Dohi O, Okayama T, Yoshida N, Kamada K, Uchiyama K, et al. Impact of primary prophylaxis with Pegfilgrastim on clinical outcomes in patients with advanced esophageal cancer receiving chemotherapy with docetaxel, cisplatin, and 5-FU. Gan To Kagaku Ryoho. 2018;45(12):1733–6.
pubmed: 30587730
Lokich J. Same-day pegfilgrastim and chemotherapy. Cancer Invest. 2005;23(7):573–6. https://doi.org/10.1080/07357900500276899 .
doi: 10.1080/07357900500276899
pubmed: 16305982
Matthews KS, Straughn JM Jr, Kemper MK, Hoskins KE, Wang W, Rocconi RP. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol. 2009;112(2):389–93. https://doi.org/10.1016/j.ygyno.2008.10.016 .
doi: 10.1016/j.ygyno.2008.10.016
pubmed: 19062080
Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract. 2010;6(3):133–40. https://doi.org/10.1200/JOP.091094 .
doi: 10.1200/JOP.091094
pubmed: 20808556
pmcid: 2868638
Linot B, Augereau P, Breheret R, Laccourreye L, Capitain O. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer. 2014;22(10):2831–7. https://doi.org/10.1007/s00520-014-2270-8 .
doi: 10.1007/s00520-014-2270-8
pubmed: 24821366
Eckstrom J, Bartels T, Abraham I, Patel H, Elquza E, Scott AJ, Malangone S, Hollings J, McBride A. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. Support Care Cancer. 2019;27(3):873–8. https://doi.org/10.1007/s00520-018-4373-0 .
doi: 10.1007/s00520-018-4373-0
pubmed: 30090991
Ludwig H, Gascon P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio(R)) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study. Support Care Cancer. 2019;27(6):2301–12. https://doi.org/10.1007/s00520-018-4513-6 .
doi: 10.1007/s00520-018-4513-6
pubmed: 30343410
Ishikawa T, Yasuda T, Okayama T, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Shiozaki A, et al. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: a phase II study. Cancer Sci. 2019;110(12):3754–60. https://doi.org/10.1111/cas.14218 .
doi: 10.1111/cas.14218
pubmed: 31646714
pmcid: 6890431
Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, Vikram R, Tu SM, Corn PG, Kim J. Safety of same-day pegfilgrastim administration in metastatic castration-resistant prostate cancer treated with cabazitaxel with or without carboplatin. Clin Genitourin Cancer. 2017;15(3):e429–35. https://doi.org/10.1016/j.clgc.2016.12.003 .
doi: 10.1016/j.clgc.2016.12.003
pubmed: 28038931
Hoffmann PS. Administration of pegfilgrastim on the same day or next day of chemotherapy. J Clin Oncol. 2005;23:8137–8137.
doi: 10.1200/jco.2005.23.16_suppl.8137
Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT, Weycker D. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer. 2017;25(8):2619–29. https://doi.org/10.1007/s00520-017-3703-y .
doi: 10.1007/s00520-017-3703-y
pubmed: 28484882
Matera RM, Relias V, Saif MW. Safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for gastrointestinal malignancies. Cancer Med J. 2021;4(1):6–11.
pubmed: 32656544
Lokich J. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol. 2006;29(4):361–3. https://doi.org/10.1097/01.coc.0000217816.16236.22 .
doi: 10.1097/01.coc.0000217816.16236.22
pubmed: 16891862
Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer. 2016;24(5):2309–16. https://doi.org/10.1007/s00520-015-3036-7 .
doi: 10.1007/s00520-015-3036-7
pubmed: 26607482
Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged >/=65 years: a retrospective evaluation using medicare claims. Curr Med Res Opin. 2018;34(9):1705–11. https://doi.org/10.1080/03007995.2018.1495621 .
doi: 10.1080/03007995.2018.1495621
pubmed: 29962268
Kajiyama Y. New Japanese classification of esophageal cancer (11th Edition). Gan To Kagaku Ryoho. 2016;43(9):1049–52.
pubmed: 27996228
Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy. 2003;23(8):15S-19S. https://doi.org/10.1592/phco.23.9.15s.32889 .
doi: 10.1592/phco.23.9.15s.32889
pubmed: 12921218
Basu S, Hodgson G, Katz M, Dunn AR. Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood. 2002;100(3):854–61. https://doi.org/10.1182/blood.v100.3.854 .
doi: 10.1182/blood.v100.3.854
pubmed: 12130495
Furze RC, Rankin SM. Neutrophil mobilization and clearance in the bone marrow. Immunology. 2008;125(3):281–8. https://doi.org/10.1111/j.1365-2567.2008.02950.x .
doi: 10.1111/j.1365-2567.2008.02950.x
pubmed: 19128361
pmcid: 2669132
Knudsen E, Iversen PO, Boyum A, Seierstad T, Nicolaysen G, Benestad HB. G-CSF enhances the proliferation and mobilization, but not the maturation rate, of murine myeloid cells. Eur J Haematol. 2011;87(4):302–11. https://doi.org/10.1111/j.1600-0609.2011.01658.x .
doi: 10.1111/j.1600-0609.2011.01658.x
pubmed: 21623923
Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104(11):1455–60. https://doi.org/10.1111/cas.12274 .
doi: 10.1111/cas.12274
pubmed: 23991649
pmcid: 7654256
Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34. https://doi.org/10.1038/bjc.2016.350 .
doi: 10.1038/bjc.2016.350
pubmed: 27811857
pmcid: 5129815
Isenberg JS, Vinod-Kumar S, White G, Ojeifo JO. Hematopoietic stem cells mobilization and immune response in tumor-bearing mice. Ann Plast Surg. 2004;52(5):523–30. https://doi.org/10.1097/01.sap.0000123355.38162.d3 .
doi: 10.1097/01.sap.0000123355.38162.d3
pubmed: 15096946